

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. Midwest Division - LSH, LLC d/b/a Lee's Summit Hospital  2. 2100 S.E. Blue Parkway Lee's Summit, MO 64063		In accordance with letter dated July 26, 2022,	4. Expiration Date: June 30, 2037
		3. License No.: 24-24660-01 is amended in its entirety to read as follows:	5. Docket No.: 030-29074 Reference No.:
6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1 curie total	C. For any use permitted by 10 CFR 35.300.
D. Any byproduct material permitted by 10 CFR 31.11	D. Prepackaged Kits	D. 2 millicuries total	D. For use in in-vitro studies.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 24-24660-01

Docket or Reference No.:  
030-29074

Amendment No. 44

**CONDITIONS**

10. Licensed material shall be used or stored at the licensee's facilities located at 2100 S.E. Blue Parkway, Lee's Summit, Missouri, 64063.

11. The Radiation Safety Officer (RSO) for this license is Nicholas Bell, BS, CNMT, PET.

12. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User (M.D., D.O., etc.)Material and Use

Sri Krisha Alapati, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to oral administration of sodium iodide I-131)

Craig M. Bruner, M.D.

10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

William M. Chase, M.D.

10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Jeffrey R. Conaway, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Daniel H. Dunker, M.D.

10 CFR 35.200

John F. Eurich, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Sujit R. Gandhari, M.D., M.P.H.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to oral administration of sodium iodide I-131)

Vandana Halder, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Daniel Eric Hatfield, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Jason Eric Himmel, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Nathaniel R. Jewell, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to oral administration of sodium iodide I-131)

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 24-24660-01

Docket or Reference No.:  
030-29074

Amendment No. 44

Authorized User (M.D., D.O., etc.)

Nathan S. Johnson, M.D.

Joseph Phillip Koury, M.D.

Aaron M. Lewis, M.D.

Drew Moore, M.D.

Douglas W. Nemmers, M.D.

Olufolajimi Obembe, M.D.

Amy P. Oberhelman, M.D.

Bradley Ritland, M.D.

Michael Brian Robertson, M.D.

James E. Sear, M.D.

Curtis T. Selser, M.D.

Ricki Shah, M.D.

Donald J. Stallard, M.D.

Material and Use

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to oral administration of sodium iodide I-131)

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to oral administration of sodium iodide I-131)

10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to oral administration of sodium iodide I-131)

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to oral administration of sodium iodide I-131)

10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to oral administration of sodium iodide I-131)

10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to oral administration of sodium iodide I-131)

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to oral administration of sodium iodide I-131)

10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**


License No.: 24-24660-01

Amendment No. 44

Docket or Reference No.:  
030-29074

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those statements, representations, and procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence impose on the licensee requirements that are more restrictive than or in addition to the regulations.

- A. Application dated January 26, 2022 (ML22039A057)
- B. Letter dated May 24, 2022 (ML22145A136)
- C. Letter dated July 26, 2022 (ML22235A639)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: October 7, 2022By: \_\_\_\_\_  
Laura B. Cender  
Region 3